Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Esophageal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Radiotherapy 7Cisplatin 7Irinotecan 5Fluorouracil 5pembrolizumab 4Docetaxel 4Paclitaxel 3Oxaliplatin 3durvalumab 2Radiation 2Nivolumab 2Magnetic Resonance Spectroscopy 2Leucovorin 2Drug Therapy 2Carboplatin 2vandetanib 1toripalimab 1tislelizumab 1spartalizumab 1ribociclib 1obinutuzumab 1naptumomab estafenatox 1matuzumab 1futibatinib 1adavosertib 1Vorinostat 1Topotecan 1Taxes 1Surgical Procedures, Operative 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Adenocarcinoma Of Esophagus × matuzumab × Clear all
NCT00113581 2014-02-19

Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
26 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡